Our Technology

Engineering Fit-for-Purpose Biotherapeutics

Our technology leverages Zymeworks’ industry leading expertise in the fields of protein engineering and drug chemistry to discover and develop the next generation of antibody-based therapeutics to combat unmet medical need in hard-to-treat cancers and other serious diseases.

The integration of complementary and antibody-based technologies, embedded in our proprietary Multispecific and Antibody-Drug Conjugate (ADC) therapeutic modalities, interfaced with disease biology, enables the development of differentiated and fit-for-purpose therapeutics.

Select Difficult-to-Treat Cancers & Target

Design with Complementary Technology

Optionality with Two Foundational Fit-for-Purpose Modalities